The High Cost of Late Understanding: Why Predictive Multi-Omics Must Come Before Clinical Trials

Pharmaceutical companies invest an average of $2.6–$3 billion and 12–15 years to bring a single new molecular entity (NME) to market. Yet, even after a drug has received regulatory approval, major biological questions too often remain unanswered:

• Why do some patients respond and others do not, despite appearing clinically similar?
• Why does resistance emerge, sometimes within months of treatment?
• How should patients be stratified to maximize efficacy and minimize harm?

These are not post-hoc refinements, they are fundamental to the drug’s mechanism of action, clinical utility, and ultimately, commercial viability. And they are too often answered after market entry, when the cost of course correction is at its peak.

The reason for this delay is not the absence of data, but the inadequacy of current tools, models, and development paradigms.

Linear Pipelines in a Nonlinear Biological World

The traditional drug development model remains reductionist and linear: target identification → hit validation → preclinical models → staged clinical trials. At each step, assumptions about disease biology and patient response are baked into study design, often based on incomplete or oversimplified data. These assumptions are rarely stress-tested until late-stage trials or post-market surveillance.

Real-world consequences abound:

• EGFR inhibitors in non-small cell lung cancer initially targeted patients with sensitizing EGFR mutations. Yet acquired resistance emerged quickly. Mechanisms such as T790M mutations, MET amplification, and histologic transformation were only discovered post-approval. A more holistic approach integrating longitudinal multi-omics during development could have modeled these resistance pathways prospectively.
• Checkpoint inhibitors like pembrolizumab were approved with PD-L1 expression as a biomarker. But PD-L1 alone poorly predicts response across cancer types. Years later, studies integrating transcriptomics, TCR repertoire sequencing, tumor mutational burden (TMB), and even microbiome profiling revealed deeper insights into immune responsiveness, insights that could have refined inclusion criteria and trial design much earlier.
• Alzheimer’s disease: Repeated failures of β-amyloid targeting drugs (e.g., bapineuzumab, solanezumab) revealed a glaring gap between preclinical target validation and human disease complexity. Without multi-omics stratification of patient subtypes and pathology trajectories, the field spent over a decade pursuing potentially non-causal targets.

The pattern is clear: trial-and-error dominates, even in the era of precision medicine. Biology remains insufficiently understood at the time of pivotal decisions. Regulators and payers are increasingly demanding mechanistic clarity and biomarker-driven evidence, not just statistical significance in subgroups.

Existing Tools Are Not Enough

The tools used during early discovery and translational research are fundamentally limited:

• Bulk transcriptomics and proteomics dilute cellular heterogeneity, masking crucial disease-driving subpopulations.
• Single-modality approaches (e.g., genomics-only or proteomics-only) fail to capture the full regulatory and signaling context of complex diseases.
• Conventional statistics identify correlative markers, but not causal, mechanistic ones, let alone predictive markers transferable across cohorts.
• Reproducibility is a persistent crisis: over 70% of academic biomarker discoveries fail to replicate, largely due to overfitting, cohort-specific biases, and lack of validation across modalities.

Even advanced bioinformatics pipelines rarely integrate data across omics layers (e.g., genome → transcriptome → epigenome → proteome) in a way that respects biological interdependencies.